Biotricity Inc (BTCY) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...

Yahoo

19-07-2025

Revenue (Q4 2025): $3.7 million, a 16.5% increase year-over-year.
Revenue (Fiscal Year 2025): $13.8 million, up 14.3% from the prior year.
Gross Profit (Q4 2025): $3 million, a 31% increase from the prior year period.
Gross Margin (Q4 2025): 80.4%, an improvement of over 890 basis points from the prior year.
Operating Expenses (Fiscal Year 2025): $13 million, a 24.5% decrease from the prior year.
Net Loss (Fiscal Year 2025): $11.9 million, compared to $14.9 million in the prior year.
Net Loss Per Share (Fiscal Year 2025): $0.555, compared to $1.66 in the prior year.
Adjusted EBITDA (Q4 2025): Positive $438,000, corresponding to $0.017 per share.
Adjusted EBITDA (Fiscal Year 2025): Loss of just under $1 million, improved from a loss of $7.8 million in fiscal '24.
Warning! GuruFocus has detected 6 Warning Signs with BTCY.
Release Date: July 18, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
Biotricity Inc (BTCY) achieved a 16.5% year-over-year revenue increase in the fourth quarter, reaching $3.7 million.
The company expanded its Cardiac AI cloud platform through strategic partnerships with Amazon AWS and Google's TensorFlow, enhancing diagnostic accuracy and patient outcomes.
Biotricity Inc (BTCY) secured strategic alliances with three major group purchasing organizations, providing access to approximately 90% of U.S. hospitals.
The company achieved positive adjusted EBITDA of $438,000 in the last quarter of fiscal 2025, indicating progress towards profitability.
Biotricity Inc (BTCY) received regulatory approval in Saudi Arabia, aligning with its strategy to expand internationally and improve patient outcomes.
Negative Points
Biotricity Inc (BTCY) reported a net loss attributable to common stockholders of $11.9 million for the fiscal year ended March 31, 2025.
The sales cycles for new partnerships and pilots with GPOs are lengthy, potentially delaying revenue realization.
Despite improvements, the company still faces challenges in achieving profitability, with a net loss per share of $0.555 for the fiscal year.
The company lacks in-house expertise to monetize its extensive data set, which could be a missed opportunity for additional revenue.
Biotricity Inc (BTCY) anticipates that international market revenue contributions, such as from Saudi Arabia, may not significantly impact financials until 2026.
Q & A Highlights
Q: When can we expect greater acceleration in terms of revenue from your GPO relationships? A: Waqaas Al-Siddiq, CEO: The GPOs involve long sales cycles, often taking up to a year. We are currently engaging in pilots with large, multistate organizations. Revenue will start to trickle in as these pilots conclude and roll out over the next few quarters.
Q: Which cost levers give you confidence that margins can stay above 80% in 2026? A: Waqaas Al-Siddiq, CEO: Our technology, particularly data analysis and device output, provides high margins. We've achieved economies of scale, reducing costs for each new device added to our platform, which helps maintain high margins.
Q: Can the data set of over 1 trillion heartbeats be monetized beyond improving clinical algorithms? A: Waqaas Al-Siddiq, CEO: Yes, there is potential to monetize this data, especially given the focus on cardiac health. While we currently lack the in-house skill set to package and sell this data, we plan to invest in this area as we reach profitability.
Q: What are your efforts in pursuing FDA clearance for your AI clinical model? A: Waqaas Al-Siddiq, CEO: We are in the process of analyzing data and bringing in experts for secondary input. We plan to present this to the FDA in a pre-submission meeting to ensure our approach aligns with their requirements. This is a complex process, but we are targeting significant opportunities.
Q: How do you see the Saudi Arabian market impacting revenue for the rest of 2025 and next year? A: Waqaas Al-Siddiq, CEO: We expect significant impact in 2026. We aim for 20-30% of our business to be international in the coming years. For next year, we anticipate $0.5 million to $1 million in added revenue from international distribution partnerships.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Error al recuperar los datos
Inicia sesión para acceder a tu cartera de valores
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos